Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06LFV
|
|||
| Former ID |
DCL000179
|
|||
| Drug Name |
NM-702
|
|||
| Synonyms |
NM-702; Parogrelil hydrochloride; UNII-65O9DMS368; 65O9DMS368; NM702; NM 702; 878796-94-2; SCHEMBL1739368; QWGUGDYWUADMGB-UHFFFAOYSA-N; 3(2H)-Pyridazinone, 4-bromo-6-(3-(4-chlorophenyl)propoxy)-5-((3-pyridinylmethyl)amino)-, hydrochloride (1:1); 139145-84-9; 4-bromo-6-(3-(4-chlorophenyl)propoxy)-5-(3-pyridylmethylamino)-3(2H)-pyridazinone hydrochloride
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Angina pectoris [ICD-11: BA40; ICD-9: 413] | Phase 3 | [1] | |
| Company |
Nissan Chemical America
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H19BrCl2N4O2
|
|||
| Canonical SMILES |
C1=CC(=CN=C1)CNC2=C(C(=O)NN=C2OCCCC3=CC=C(C=C3)Cl)Br.Cl
|
|||
| InChI |
1S/C19H18BrClN4O2.ClH/c20-16-17(23-12-14-3-1-9-22-11-14)19(25-24-18(16)26)27-10-2-4-13-5-7-15(21)8-6-13;/h1,3,5-9,11H,2,4,10,12H2,(H2,23,24,26);1H
|
|||
| InChIKey |
QWGUGDYWUADMGB-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 878796-94-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Phosphodiesterase (PDE) | Target Info | Inhibitor | [2] |
| Thromboxane-A synthase (TBXAS1) | Target Info | Inhibitor | [2] | |
| BioCyc | C20 prostanoid biosynthesis | |||
| KEGG Pathway | Arachidonic acid metabolism | |||
| Metabolic pathways | ||||
| Platelet activation | ||||
| Pathwhiz Pathway | Arachidonic Acid Metabolism | |||
| WikiPathways | Prostaglandin Synthesis and Regulation | |||
| Arachidonic acid metabolism | ||||
| Phase 1 - Functionalization of compounds | ||||
| Eicosanoid Synthesis | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication. Trials. 2011; 12: 134. | |||
| REF 2 | The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease. J Am Coll Cardiol. 2006 Dec 19;48(12):2539-45. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.